Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.36 |
| ▸ | CA12 | O43570 | 3/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | KIF11 | P52732 | 1/20 | 0.30 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.30 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18426392 | 0.88 | CA14 (0.34) | CA14CA12CA2CA1KIF11 | |
| SCHEMBL15122705 | 0.88 | CA14 (0.34) | CA14CA12CA2CA1KIF11 | |
| SCHEMBL15122706 | 0.88 | CA14 (0.34) | CA14CA12CA2CA1KIF11 | |
| SCHEMBL27257668 | 0.82 | CA14 (0.37) | CA14CA12CA2CA1KIF11 | |
| SCHEMBL13570150 | 0.82 | CA14 (0.38) | CA14CA12CA2CA1HDAC3 | |
| SCHEMBL883067 | 0.81 | CA2 (0.39) | CA14CA12CA2CA1HDAC1 | |
| SCHEMBL20262979 | 0.81 | CA14 (0.42) | CA14CA12CA2CA1HDAC3 | |
| SCHEMBL8155894 | 0.80 | CA14 (0.38) | CA14CA12CA2CA1HDAC1 | |
| SCHEMBL6276163 | 0.80 | CA14 (0.36) | CA14CA12CA2CA1KIF11 | |
| SCHEMBL23189118 | 0.79 | SLC7A5 (0.35) | CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10640534-B2 | Therapeutically active compositions and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2020-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10640534-B2 | Therapeutically active compositions and their methods of use | IDH1, IDH3B, IDH3A | CA14 1360/4885CA12 803/4885CA2 1508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.